Private equity firm ChrysCapital injected approximately ₹600 crore into La Renon Healthcare, headquartered in Ahmedabad. La Renon currently garners the bulk of its revenue from segments such as nephrology, central nervous system (CNS), critical care (CC), and gastroenterology (GE). The company holds a significant position in the domestic formulations market, while exports contribute to 40-45% of its overall sales.
Ranked as the twenty-fourth fastest-growing pharmaceutical company in India, La Renon boasts a strong presence in several niche and chronic therapeutic areas. Its nutritional supplement brand, nuhenz tablet, features among the top three-hundred formulation brands domestically.
Kshitij Sheth, Managing Director of ChrysCapital, expressed confidence in La Renon’s growth trajectory, citing its transformative potential. La Renon has diversified into consumer brands, introducing innovative products like Dente 91 for oral health and Whey 91 for protein supplements. As reported by Asia Today, the company operates two manufacturing units, two API facilities (one of which is USFDA approved), and an in-house R&D center.
